Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals

In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15

(2018) Krystyna M Kazmierczak et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Mutation-Driven Evolution of Pseudomonas aeruginosa in the Presence of either Ceftazidime or Ceftazidime-Avibactam

(2018) Fernando Sanz-García et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms

(2016) Gabriel Torrens et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins

(2015) M. Berrazeg et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1

(2015) Diansy Zincke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii : Mechanisms and epidemiology

(2015) Anaïs Potron et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of ceftazidime/avibactam against isogenic strains ofEscherichia colicontaining KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop

(2015) Marisa L. Winkler et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from U.S. Hospitals

(2014) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa

(2014) Marisa L. Winkler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12)

(2014) Helio S. Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Characterization of a novel Zn2+-dependent intrinsic imipenemase from Pseudomonas aeruginosa

(2014) Alicia Fajardo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries

(2014) M. Castanheira et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases

(2013) Sushmita D. Lahiri et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pseudomonas Aeruginosa: Resistance to the Max

(2011) Keith Poole   Frontiers in Microbiology

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters

(2010) S. Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Impact of multidrug-resistantPseudomonas aeruginosainfection on patient outcomes

(2010) Elizabeth B Hirsch et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa

(2009) J.-M. Rodriguez-Martinez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms

(2009) P. D. Lister et al.   CLINICAL MICROBIOLOGY REVIEWS